Unknown

Dataset Information

0

Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.


ABSTRACT: The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL-302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL-302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong candidate for PIM/PI3K/mTOR inhibition. IBL-302 was more effective than single PI3K inhibition in vitro, and IBL-302 treatment of neuroblastoma patient-derived xenograft (PDX) cells induced apoptosis, differentiated tumor cells, and decreased N-Myc protein levels. IBL-302 further enhanced the effect of the common cytotoxic chemotherapies cisplatin, doxorubicin, and etoposide. Global genome, proteome, and phospho-proteome analyses identified crucial biological processes, including cell motility and apoptosis, targeted by IBL-302 treatment. While IBL-302 treatment alone reduced tumor growth in vivo, combination therapy with low-dose cisplatin inhibited neuroblastoma PDX growth. Complementing conventional chemotherapy treatment with PIM/PI3K/mTOR inhibition has the potential to improve clinical outcomes and reduce severe late effects in children with high-risk neuroblastoma.

SUBMITTER: Mohlin S 

PROVIDER: S-EPMC6685085 | biostudies-other | 2019 Aug

REPOSITORIES: biostudies-other

altmetric image

Publications


The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL-302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL-302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong candidate for PIM/PI3K/mTOR inhibition. IBL-302 was more effective than single PI3K inhibition in vitro, and IBL-302 treatment of neuroblastoma patient-derived xenograft (PDX) cells induced apoptosis, dif  ...[more]

Similar Datasets

| S-SCDT-EMM-2018-10058-T | biostudies-other
2019-07-11 | PXD014234 | Pride
2019-06-22 | GSE133137 | GEO
| S-EPMC7118022 | biostudies-literature
| S-EPMC10635512 | biostudies-literature
| PRJNA550081 | ENA
| S-EPMC8125027 | biostudies-literature
| S-EPMC8591745 | biostudies-literature
| S-EPMC6279580 | biostudies-literature
| S-EPMC5029652 | biostudies-literature